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The aim of this study was to determine the best upper age limit for a breast cancer screening programme. We 
used a model-based study using optimistic and pessimistic assumptions, concerning improvement of prognosis 
due to screen-detection and duration of the period of mammographic detectability, resulting in upper and lower 
limits for favourable and unfavourable effects. Under pessimistic assumptions, the balance between positive and 
negative effects of screening remains favourable up to an age of around 80 years. Under optimistic assumptions, 
this balance never becomes clearly negative with increase of the upper age limit of a screening programme. When 
including the costs in the analysis, the balance between effects and costs of increasing the upper age limit from 69 
to 75 years is likely to be at least as favourable as intensifying a screening programme within the age group SO-69 
years. A further increase leads to a markedly less favourable balance. Competing causes of death do not lead to 
missing net benefit for women up to at least age 80 years, but the disproportional rise of negative effects of 
screening with age in older women leads to a lower cost-effectiveness ratio than intensifying screening at ages 
50-69 years. 
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INTRODUCTION 
SETTING UPPER and lower age limits for a mass screening 
programme for breast cancer must be well justified as breast 
cancer is an important disease in younger as well as older women. 
In the U.K. screening programme, women are invited for 
screening every 3 years between age 50 and 65 years [ 11. In the 
Dutch programme, women are invited for screening every other 
year between 50 and 70 years of age [2]. In the U.S.A., 
most institutions which give advice concerning breast cancer 
screening do not give an upper age boundary 131. 
The lower boundary of age 50 years has been justified by the 
published results of randomised trials which show a much lower 
(and statistically non-significant) reduction in breast cancer 
mortality for those who entered the trial under the age of 50 
years as compared to women who entered at higher ages [4]. 
This difference in effectiveness can be explained by physical 
changes which occur around the time of menopause (such as 
radiographic density of the breast and tumour growth rate) and 
which influence detection rates and the earliness of detection by 
mammography. 
There is no such clear-cut justi6cation of an upper boundary. 
The relevant biology for this decision is complicated. Breast 
cancer mortality rates are higher in older women. Therefore 
screening of an older population can lead to more prevented 
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breast cancer deaths than screening of a younger population. 
However, the number of life-years gained by preventing a 
breast cancer death by screening rapidly decreases with age of 
detection, because life expectancy decreases with age. Neverthe- 
less, in the Netherlands, life expectancy of a 70-year-old woman 
is still 15 years [5]. 
The increasing rates for mortality from causes other than 
breast cancer leads to a higher probability of women dying from 
other causes in the lead-time period. As a consequence, the 
number of extra incident cases generated by screening relative 
to the number of prevented breast cancer deaths increases with 
age at screening. This unfavourable effect of screening also 
increases with longer lead time, which is roughly proportional 
to the duration of the preclinical period of mammographic 
detectability. 
So, on the one hand, an equal amount of screenings at higher 
ages will lead to more prevented breast cancer deaths, while on 
the other hand, there is a less favourable balance between the 
positive and negative ffects of screening. 
The latest publication on the Swedish randomised trials [4] 
reports a point estimate for mortality reduction in the age group 
70-74 years which is much lower than for the age group 
50-69 years. Since there is no biological explanation for such a 
difference, and the number of cases involved is very small, it 
Seems reasonable to explain this difference by random fluctu- 
ation. However, the present lack of another explanation should 
not lead to neglecting the possibility that breast cancer screening 
2040 
does lead to a smaller improvement of prognosis over the age of because here an estimate of social costs is made, which is strongly 
70 years [6]. inlhtenced by attendance. These attendance rates decline from 
This paper attempts to determine the best upper age limit 75% at age 51 years, to 61% at age 71 years and 21% at age 81 
for breast cancer screening, once the decision to organ& a years. The assumptions about social costs have been described 
programme has been taken. The balance between favourable in detail by de Koning and associates [8] using 1990 as the base 
and tmfavourable ffects is considered, as is the balance between year for discounting and the start of the build up of the 
costs and effects. There are not many data available about the programme. The applied exchange rate is 2.7 Dutch guilders of 
effects of screening for breast cancer in women older than 70 1990 per pound. 
years. It is, therefore, not possible to give a precise assessment 
of what is to be expected from mass screening in older women. RESULTS 
However, the determinants of such an upper age limit are Preclinical period 
identified and, on basis of the existing uncertainty concerning A measure of the duration of the preclinical period of mammo- 
these determinants, margins of possible outcomes are set. graphic detectability is the ratio between detection rates at first 
MATERIALS AND METHODS 
screening and incidence rates in the situation without screening. 
The MISCAN model for underlying natural history of breast 
Table 1 shows the comparison of results from screening projects 
cancer and the impact of screening, which has been used for this 
which have enrolled women over 70 years and simulated results. 
analysis, has been described elsewhere [7]. The disease model is 
It is clear that preclinical duration strongly increases between 
based on a three-stage division of the development of invasive 
ages 50 and 70 years. Comparison of the screening results from 
breast cancer in which the stage reflects tumour size. A pro- 
the Kopparberg/&tergiitland trial with the incidence in the 
portion of the invasive breast cancers is preceded by a screen- 
control group seems to show a further increase in preclinical 
detectable ductal carcinoma in situ (dCIS). The screen-detectable 
duration at higher ages [9]. However, a comparison with inci- 
stages have an exponentially distributed sojourn time with an 
dence from the Swedish cancer registry suggests a stabilising 
age-dependent mean. Most model assumptions are identical to 
preclinical duration after 60 years of age. The results from the 
those used for the Dutch cost-effectiveness analysis which 
Nijmegen trial and the BCDDP show at most a slow increase of 
focused on screening between the ages of 50 and 70 years. This 
preclinical duration at ages over 70 years. 
model reflects estimates of health effects and social costs of the 
primary process of screening, changes in diagnostic procedures, 
Two muin variants 
primary therapies, follow-up after treatment, metastatic disease, 
Table 2 shows the main positive effect of screening: life-years 
terminal illness and breast cancer mortality when a 2-yearly 
gained, and two important negative effects: life-years in lead 
screening programme is carried out during a period of 27 years, 
time (that is time with knowledge of the disease outside the 
after which time the maximum impact of screening on mortality 
gained life-years) and extra incidence caused by screening. These 
is reached [8]. The assumptions which are specifically relevant 
are the expected results of a screening programme which starts 
for screening in older women have been studied in more detail 
at age 5 1 years and continues screening with 2-year intervals up 
by relating them to the results of trials which included women 
to the upper age limits indicated. From around age 90 years 
over the age of 70 years, that is, the study in Kopparberg/ 
further extension of the screening programme leads to so few 
ijstergiitland [9], the Dutch pilot project of Nijmegen 
extra life years gained, that the increase cannot be distinguished 
(unpublished data) and the BCDDP [lo]. 
from the random fluctuation of the model. It also shows that the 
expected number of life-years gained is not very different in the 
Model variants optimistic and pessimistic variants. The important difference 
Two main variants were used: the ‘optimistic variant’ which between the two variants is the level of negative effects. 
assumes no further increase in preclinical duration after the age With extension of a screening programme to higher ages, the 
of 65 years and the ‘pessimistic variant’ assumes afuther increase number of extra years in lead time and the number of extra 
in preclinical duration with age which is extrapolated from the 
trend in younger age groups. Table 1. Ratioofdetection rateatprevalencescreeningandimihce 
The model results have been integrated in one outcome rate in situation u&out screening of diffmtu screening pwjects 
measure: 5% discounted quality adjusted life years (QALYs) 
gained. The number of QALYs gained by a screening pro- Kopparberg/ 
gramme is calculated by attributing utilities to each health state iistergiitland Simulated 
that is relevant for breast cancer screening and by multiplying 
these utilities with the number of life years in each of these Age Incidence Incidence 
health states. The difference between the total number of class control cancer Nijmegen Optimistic Pessimistic 
QALYs in a situation with a screening programme and the total (ye& group registry BCDDP trial variant variant 
number of QALYs in the situation without screening is the 
number of QALYs gained [ 111. In this way, not only the effects - 19 
45-49 . 
1.8 
3.0 1.0 
of screening on mortality are taken into account, but also the 3.8 2.5 
impact of diagnostic procedures, primary therapy, follow-up 
5G54 3. 
55-59 . 
3.5 
3.3 2.8 2.0 2.0 
after treatment, metastatic disease and terminal illness. 
4.0 2.4 2.3 2.3 
2.5 2.8 2.8 
For demonstration purposes, an attendance rate of 100% is 4.7 
3.6 
7.2 3.4 3.4 
assumed. This gives the sharpest contrast between different 70-74 5.4 4.4 
4.7 
3.0 3.6 4.6 
variants. 75-79 - - - 4.0 3.9 6.0 
For calculating cost-effectiveness ratios, an attendance pat- 80-84 - - - 3.4 4.0 8.4 
tern, as that of the Nijmegen trial (unpublished data) has been 
assumed. A realistic attendance pattern has been assumed Sources [9, lo]. 
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Table 2. Life-years gained, &e-years in lead time and extra number 
of incidents of breast cancer to be expectedjknn a screeningprogramme 
with 100°/o attendance and invitations every 2 years starting at age 
5 1 years; results fm the optimistic and pessimistic variants 
Upper age Life-years gained Life-years in lead Extra incidence 
(* 1000) time (*lOOO) (cases) 
opt. pes. opt. pes. opt. pes. 
69 408 395 357 377 5266 6258 
71 428 416 3% 433 6593 8304 
73 448 436 433 495 7946 11 089 
75 463 450 468 560 9406 14 633 
77 475 466 495 632 10 831 19 437 
79 480 476 517 703 12 205 25 142 
81 486 483 538 776 13 864 32 356 
83 491 489 556 848 15 582 40647 
85 494 492 570 909 17 165 49 273 
87 495 495 580 973 18 547 59 816 
89 494 496 586 1024 19 656 69 392 
99 497 497 597 1057 22 288 77 760 
opt. )optimistic; pes. )pessimistic 
incident cases increases much more rapidly than the number 
of life-years gained. The pessimistic variant shows that with 
extending the screening programme from age 79 years to age 8 1 
years, gaining 1 extra life-year in the population coincides with 
1 extra breast cancer case (leading to 1 extra primary treatment) 
and leads to more than 10 extra life-years with knowledge of the 
disease outside the gained life-years. 
Figure 1 shows the number of 5% discounted QALYs gained 
as a function of the upper age limit of invitation for screening of 
a programme with 2-year screening intervals, starting at age 5 1 
years. There is a wide range between the optimistic and the 
pessimistic variant. The optimistic variant shows no clear 
decrease in the expected number of QALYs gained at any 
increase of the upper age of the screening programme. In the 
pessimistic variant, the balance of favourable and unfavourable 
effects (measured in 5% discounted QALYs) becomes negative 
if screening is continued beyond age 80 years. Therefore, it is 
very likely that when extending a mass screening project up to 
120 r 
Optimistic 
851 I / I I I 
IQ 75 80 85 90 95 100 
Last screening age (years) 
Fii 1. The number of 5% discounted QALYs gained as a function 
of the upper age limit of invitation for screening of a programme with 
2-year screening intervals, starting at age 51 years. 
around age 80 years or even higher the balance between positive 
and negative ffects remains favourable. 
Cost-effectiveness 
The marginal cost-effectiveness ratio (CER) in the pessimistic 
variant of extending a programme from a last age of invitation of 
69 years to a last invitation at 75 years is MOO per QALY 
gained. This is approximately the same ratio as results from 
intensifying the invitation scheme in the age group of 50-70 
years old. Further extension to age 79 years has a marginal CER 
of f36 000 per QALY gained. 
No improvement of prognosis 
A model which consists of the same assumptions as the 
pessimistic model used for cost-effectiveness analyses, but with 
no improvement of prognosis due to screening at ages 70+ years 
(therefore very close to the point estimates of the Swedish 
randomised trials), leads to results as shown in Table 3. As 
expected in such a situation, this would have detrimental effects. 
Screening over 70 years could lead to doubling of the years in 
lead time and quadrupling of the extra incidence from 0.6% to 
2.4%. 
DISCUSSION 
The conclusion of Forrest [ 12, 131 concerning the upper 
boundary of screening is that because of the rapid fall in 
attendance after the age of 64 years, the invitation scheme of a 
screening programme should not include higher age groups. 
From a cost-effectiveness point of view, this seems like an 
overestimate of the cost of sending out invitations for screening. 
The cost of inviting women is relatively low as compared to 
the other costs, therefore a lower attendance rate should not 
automatically lead to an upper age limit in the invitation scheme. 
Besides the upper age limit for issuing invitations, Forrest 
recommended encouraging older women to get screening with- 
out invitation; for which they do not mention an upper age limit. 
This recommendation does not acknowledge that from a certain 
age, the unfavourable effects of screening outweigh the favour- 
able effects. Both recommendations together lead to under- 
serving women just over 65 years as well as possibly harmful 
screening of very old women. 
For an estimation with any precision of the costs and effects 
of a mass screening project for women over 70 years, more data 
on the effects of screening are needed, especially on preclinical 
duration of the phase of mammographic detectability. The 
available data leave room for a wide range of possible conse- 
quences. Nevertheless, some conclusions can be drawn. 
Both main variants of the model assume an improvement of 
Table 3. Liferears gained, liferears in lead time, extra number of 
incident cases of breast cancer and 5% discounted QALYs gained, to 
be expected jkm a screening programme with a realistic attendance 
and invitation starting at age 5 1 years; results fm pessimistic variant 
without any improvement of prognosis due to screening 
Upper age Life-years Life-years in Extra QALYs 
limit (years) gained lead time incidence gained (5% 
(*looo) (* looo) (cases) disc.) 
69 292 275 4651 62 727 
99 292 463 17663 57 855 
disc., discounted. 
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prognosis due to screen-detection of breast cancer, which is the 
same for women of all ages. We are aware of the fact that the 
results from the Swedish random&d trials show a mortality 
reduction which is far less for women in the age group of 7&74 
years than for women in the age group of SO-69 years; i.e. 2% or 
6% (depending on the way this figure is calculated) versus 29% 
(41. Only a small part of this difference can be attributed to the 
fact that the older women were invited for screening only twice, 
and that older women are less likely to attend a screening. 
However, there is no biological explanation for this substantial 
difference, so for the main variants the difference was assumed 
to be due to random fluctuation. The estimate of mortality 
reduction in the age group 70-74 years is based on very small 
numbers of deaths, and there is no significant difference in 
mortality reduction between the age groups 50-69 and 70-74 
years. 
The risk of radiation-induced cancers is not included in this 
study because of the assumption that, for screening women of 
50 to 70 years old, this effect is small in comparison with the 
other effects of screening, and even smaller when screening 
women over 70 years. Less readily quantifiable aspects of 
screening, such as a possible educational effect on women and 
the effect on quality of life after a negative screening result, have 
been omitted from the analysis, because they are assumed to be 
of negligible effect on the optimal upper age limit. 
This paper is based on a model for the Dutch situation. This 
means that assumptions made about demography, epidemi- 
ology, organisation and quality of the mass screening project and 
on costs of health care facilities are specific for the Netherlands. 
This does not imply that it is not possible to generalise the 
conclusions of this paper to other Western countries. 
Although it seems reasonable to assume an equal improvement 
of prognosis due to screen-detection for women over 70 years as 
for women from 50 to 69 years old, there is no proof of a 
favourable effect for women over 70 years. Therefore, it is also 
necessary to consider a model which assumes no improvement 
of prognosis due to screening of women over 70 years. This 
assumption is very close to the point estimate from the Swedish 
randomised trials [4]. Such a model shows that screening women 
over 70 years can lead to a considerable level of unfavourable 
effects, which in total can cost more than 8% of the QALYs that 
are expected to be gamed by a programme of screening women 
from 5 1 to 69 years old. 
The balance between favourable and unfavourable effects of 
screening can only be substantially influenced by large differ- 
ences in life expectancy at the time of screening. These kind of 
differences do not occur among countries and regions where 
organising breast cancer screening is an issue. Cost-effectiveness 
considerations also depend on the effectiveness of screening at 
ages higher than 70 years relative to screening between 50 and 
70 years which, in turn, depends on the age dependency of the 
risk for breast cancer. This age dependency is not very different 
in Western situations. 
1. 
Judging only from the number of QALYs gained, it would be 
advisable to extend breast cancer screening at least up to age 80 
years. However, because of the relatively unfavourable balance 
between positive and negative effects, the number of screens 
that is required to obtain a certain level of favourable effects is 
considerably higher than in younger age groups. The sharp 
increase of cost per QALY gained with extending a screening 
programme to higher ages, is only, to a small extent, caused by 
the cost of screening, and by far the most important cause is the 
strong increase in negative effects. When only the balance 
between favourable and unfavourable ffects is considered, mass 
screening should be continued to at least the age of 80 years, but 
when efficiency is also taken into consideration, one may be 
hesitant o offer screening to women older than 70 years because 
of an increasing cost-effectiveness ratio. 
2. 
3. 
4. 
5. 
6. 
Although the results leave a wide margin for the best upper 
age limit, not much more improvement can be expected for the 
near future, since of the two possible ways to improve on the 
estimates, one is not likely to give much better precision, the 
other is not likely to be attainable. The first is making existing 
data on screening of older women available. For instance, in the 
Kopparberg/&tergZitland study, data on women invited at ages 
over 74 years have not been published [14]. However, these data 
are based on small numbers, so it is not to be expected that 
better availability of data would greatly improve the precision of 
the estimate. The other way is, of course, a new trial. Such a 
trial can give a better understanding of the natural history of 
breast cancer in older women. However, if it is to serve as an 
investigation into the possible mortality reduction of breast 
cancer screening, a serious problem is encountered because of 
the low attendance rate to be expected in older women. Even 
where there is a strong effect of screening, low attendance leads 
to a serious dilution of the contrast between the invited and not- 
invited group. Such a trial, therefore, would need a very large 
population in order to reach an acceptable power. 
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